TY - JOUR
T1 - Consolidation therapy for ovarian cancer
AU - Huang, Gloria S.
AU - Goldberg, Gary L.
AU - Fields, Abbie L.
PY - 2005/3
Y1 - 2005/3
N2 - Purpose. To review all the published randomized trials of consolidation therapy in ovarian cancer, including chemotherapy, radiotherapy, and potential targeted/ biologic agents. Design. A Medline search was conducted to identify all publications on consolidation therapy in ovarian cancer. Proceedings of national and international meetings were also searched. Results. Platinum-based consolidation therapy is difficult to tolerate and does not confer a survival benefit. Prolonged Paclitaxel therapy lengthens the recurrence-free interval, with increased neurotoxicity. Intraperitoneal (IP) consolidation therapy is limited by marginal clinical acceptance and catheter-related complications. Oral consolidation regimens have not yet been evaluated in a randomized study. IP 32P is ineffective. Whole-abdominal radiotherapy (WAR) improves the progression-free but not overall survival in selected patients. Late radiation toxicities remain a concern with WAR. Oregovamab, an antibody to CA-125, is presently under evaluation. To date, the impact of consolidation therapy on quality-of-life remains unclear. Conclusion. An effective, minimally toxic agent for consolidation therapy in ovarian cancer has not yet been identified.
AB - Purpose. To review all the published randomized trials of consolidation therapy in ovarian cancer, including chemotherapy, radiotherapy, and potential targeted/ biologic agents. Design. A Medline search was conducted to identify all publications on consolidation therapy in ovarian cancer. Proceedings of national and international meetings were also searched. Results. Platinum-based consolidation therapy is difficult to tolerate and does not confer a survival benefit. Prolonged Paclitaxel therapy lengthens the recurrence-free interval, with increased neurotoxicity. Intraperitoneal (IP) consolidation therapy is limited by marginal clinical acceptance and catheter-related complications. Oral consolidation regimens have not yet been evaluated in a randomized study. IP 32P is ineffective. Whole-abdominal radiotherapy (WAR) improves the progression-free but not overall survival in selected patients. Late radiation toxicities remain a concern with WAR. Oregovamab, an antibody to CA-125, is presently under evaluation. To date, the impact of consolidation therapy on quality-of-life remains unclear. Conclusion. An effective, minimally toxic agent for consolidation therapy in ovarian cancer has not yet been identified.
UR - http://www.scopus.com/inward/record.url?scp=22944437773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22944437773&partnerID=8YFLogxK
U2 - 10.1080/14733400500070708
DO - 10.1080/14733400500070708
M3 - Review article
AN - SCOPUS:22944437773
SN - 1473-3404
VL - 5
SP - 3
EP - 8
JO - Women's Oncology Review
JF - Women's Oncology Review
IS - 1
ER -
